A detailed history of Morgan Stanley transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Morgan Stanley holds 534,071 shares of SGMO stock, worth $192,265. This represents 0.0% of its overall portfolio holdings.

Number of Shares
534,071
Previous 909,006 41.25%
Holding current value
$192,265
Previous $490,000 27.14%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.42 - $1.38 $157,472 - $517,410
-374,935 Reduced 41.25%
534,071 $357,000
Q4 2023

Feb 13, 2024

BUY
$0.3 - $0.63 $43,735 - $91,845
145,786 Added 19.1%
909,006 $490,000
Q3 2023

Nov 15, 2023

SELL
$0.58 - $1.47 $8,071 - $20,456
-13,916 Reduced 1.79%
763,220 $457,000
Q2 2023

Aug 14, 2023

SELL
$1.11 - $1.74 $897,763 - $1.41 Million
-808,796 Reduced 51.0%
777,136 $1.01 Million
Q1 2023

May 15, 2023

BUY
$1.66 - $3.67 $871,103 - $1.93 Million
524,761 Added 49.45%
1,585,932 $2.79 Million
Q4 2022

Feb 14, 2023

SELL
$2.77 - $5.07 $91,626 - $167,705
-33,078 Reduced 3.02%
1,061,171 $3.33 Million
Q3 2022

Nov 14, 2022

SELL
$4.27 - $6.39 $1.37 Million - $2.05 Million
-320,276 Reduced 22.64%
1,094,249 $5.36 Million
Q2 2022

Oct 27, 2022

BUY
$3.28 - $6.21 $1.82 Million - $3.45 Million
555,560 Added 64.68%
1,414,525 $5.86 Million
Q2 2022

Aug 15, 2022

BUY
$3.28 - $6.21 $1.82 Million - $3.45 Million
555,560 Added 64.68%
1,414,525 $5.86 Million
Q1 2022

Oct 27, 2022

SELL
$5.23 - $7.82 $2.91 Million - $4.34 Million
-555,560 Reduced 39.28%
858,965 $4.99 Million
Q1 2022

May 13, 2022

SELL
$5.23 - $7.82 $2.25 Million - $3.37 Million
-430,619 Reduced 33.39%
858,965 $4.99 Million
Q4 2021

Feb 14, 2022

BUY
$7.29 - $10.97 $2.07 Million - $3.11 Million
283,829 Added 28.22%
1,289,584 $9.67 Million
Q3 2021

Nov 15, 2021

BUY
$9.01 - $12.01 $9.06 Million - $12.1 Million
1,005,755 New
1,005,755 $9.06 Million

Others Institutions Holding SGMO

About SANGAMO THERAPEUTICS, INC


  • Ticker SGMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 156,552,992
  • Market Cap $56.4M
  • Description
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
More about SGMO
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.